Vipera aspis venom protein toxins

Vipera aspis venom protein toxins are a sophisticated cocktail of enzymes and non-enzymatic proteins produced by the Asp viper for subduing prey. The primary components include Phospholipase A2 (PLA2), Snake Venom Metalloproteinases (SVMPs), and Snake Venom Serine Proteases (SVSPs), which work synergistically to disrupt physiological processes (PubMed: 25462144). PLA2 enzymes are responsible for neurotoxic and myotoxic activities, while SVMPs induce hemorrhage by degrading the vascular basement membrane (UniProt). These toxins play a central role in the pathology of snakebite envenomation, causing symptoms such as local tissue necrosis, systemic coagulopathy, and cardiovascular collapse (Toxinology.com). In therapeutic settings, these proteins are the targets of polyvalent antivenoms, which utilize purified IgG or antibody fragments to neutralize the toxins' active sites. Drugs like Inoserp Europe and Antivipmyn are specifically designed to bind and clear these toxins from the circulation to prevent further damage. Monitoring the efficacy of these treatments involves tracking biomarkers like fibrinogen levels and creatine kinase to assess the resolution of coagulopathy and muscle damage. The complexity and variability of the venom across different geographical regions present a significant challenge for the development of universal neutralizing agents.

Other names

Asp viper venomVipera aspis toxinsV. aspis venom proteins

Neutralization of toxic enzymatic activity and binding sites through the administration of specific polyclonal antibody fragments (Fab or F(ab')2) that bind to the venom proteins.